Brain Inflammation Imaging for Alzheimer's Disease (ADVISe Trial)

"There is limited evidence that 11C-ER176 can be safely administered, so it achieved a score of 2."

"Presently, there exist 7 ongoing trials for 11C-ER176 with none reaching the final Stage 3. These clinical experiments are scattered across 9 locations primarily centered in Philadelphia, Pennsylvania."

"This clinical trial seeks to recruit 100 individuals between the ages of 50 and 75 who have been diagnosed with Alzheimer's. To be eligible, candidates must not demonstrate any signs of cognitive impairment or fulfil established criteria for amnestic Alzheimer’s disease, posterior cortical atrophy, or logopenic variant primary progressive aphasia; possess both written and oral fluency in English; appear likely to comply with study protocol as judged by principal investigator (PI); hold at least a Clinical Dementia Rating scale score of 0.5 upon enrollment if they are patients, while controls need to achieve an overall score of zero; appoint a surrogate decision"

"Affirmative. Per the information on clinicaltrials.gov, this experiment is actively recruiting participants and was initially posted on November 17th 2020 and most recently updated September 16th 2022. The research endeavours to recruit 100 people across a single site."

"The information on clinicaltrials.gov details that this medical experiment is presently in pursuit of subjects. This trial was first registered on November 17th 2020 and its most recent update was posted September 16th 2022."

"This medical study can only be participated in by those aged between 50 to 75 years old. However, there are alternative studies accessible for both under 18s and over 65s - 23 trials and 543 trials respectively."

"Currently, 7 clinical trials involving 11C-ER176 are active in 3 cities and 2 countries. The earliest trial of the medication was administered by Bayer back in 2010 with 161 participants taking part before reaching its endpoint. Since then, 16 further studies have been conducted."